SCHEMBL23489191

SCHEMBL23489191

NC(=O)c1c(Cl)cc(-c2ccccc2)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C2 P52895 1/20 0.53
AKR1C1 Q04828 1/20 0.53
DHODH Q02127 2/20 0.50
ESR2 Q92731 1/20 0.47
FTO Q9C0B1 1/20 0.46
RHEB Q15382 1/20 0.46
IKBKB O14920 3/20 0.46
CASP1 P29466 1/20 0.45
MAP2 P11137 1/20 0.44
MKNK1 Q9BUB5 2/20 0.43
MKNK2 Q9HBH9 2/20 0.43
CHUK O15111 2/20 0.42
BCAT2 O15382 1/20 0.42
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
PARP1 P09874 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5787358 0.83 AKR1C2 (0.61) AKR1C2AKR1C1DHODHESR2FTO
SCHEMBL27996673 0.81 SRC (0.49) FTOIKBKBCASP1MKNK1MKNK2
SCHEMBL23518353 0.80 AKR1C2 (0.53) AKR1C2AKR1C1DHODHESR2FTO
SCHEMBL6846138 0.78 BCAT2 (0.53) DHODHIKBKBMKNK1MKNK2CHUK
Urea SCHEMBL27889450 0.76 ESR2 (0.57) AKR1C2AKR1C1DHODHESR2IKBKB
SCHEMBL5785183 0.76 LMNA (0.49) AKR1C2AKR1C1FTOMAPTTSHR
SCHEMBL27979260 0.75 CASP1 (0.53) CASP1POLBPARP1TSHRHSD17B10
SCHEMBL320037 0.73 ALDH1A1 (0.61) POLBCYP3A4PARP1MAPTTSHR
SCHEMBL1002836 0.73 ALDH1A1 (0.43) AKR1C2AKR1C1CASP1POLBCYP3A4
SCHEMBL7085409 0.73 BCAT2 (0.53) IKBKBMAP2BCAT2MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530180-B2 Alpha-5 beta-1 inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-12-20 US disclosed
WO-2021222789-A1 INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-11-04 WO disclosed
WO-2021119199-A1 ALPHA-5 BETA-1 INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-06-17 WO disclosed
US-20210171455-A1 ALPHA-5 BETA-1 INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171455-A1 ALPHA-5 BETA-1 INHIBITORS SCN5A, PSMA5, API5 AKR1C2 1545/4885AKR1C1 971/4885DHODH 731/4885
US-11530180-B2 Alpha-5 beta-1 inhibitors SCN5A, PSMA5, API5 AKR1C2 1545/4885AKR1C1 971/4885DHODH 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.